Pharmaceutical Characterization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Vaccine Used for the Treatment of Superficial Bladder Cancer

1993 ◽  
Vol 82 (6) ◽  
pp. 555-562 ◽  
Author(s):  
Michael J. Groves
Keyword(s):  
Bladder Cancer ◽  
Mycobacterium Bovis ◽  
Superficial Bladder Cancer ◽  
Bcg Vaccine ◽  
Bacillus Calmette Guerin

Mycobacterium bovis Cerebellar Abscess Following Treatment With Bacillus Calmette-Guérin

2016 ◽  
Vol 30 (3) ◽  
pp. 378-380 ◽  
Author(s):  
Mollie W. Sheron ◽  
Shannon L. Holt ◽  
Christopher W. Ingram
Keyword(s):  
Bladder Cancer ◽  
Mycobacterium Bovis ◽  
Superficial Bladder Cancer ◽  
Altered Mental Status ◽  
Bacillus Calmette Guerin ◽  
Systemic Complications ◽  
Cns Infections ◽  
Antituberculosis Therapy ◽  
Cerebellar Abscess ◽  
Bcg Therapy

Bacillus Calmette-Guérin (BCG) is a live, attenuated strain of Mycobacterium bovis that is used to treat superficial bladder cancer. Although its use is typically associated with only mild, localized side effects, rare systemic complications can occur. Disseminated mycobacterium infections after BCG therapy have been reported in over 30 cases; however, central nervous system (CNS) infections do not commonly occur. We report a 74-year-old male who developed a M. bovis cerebellar abscess after receiving intravesical BCG infusion for bladder cancer for less than 1 year. This patient was successfully treated with antituberculosis therapy and corticosteroids. This patient case demonstrates that early-onset M bovis CNS infections can occur after BCG therapy. Patients presenting with altered mental status while on BCG therapy should be evaluated for disseminated infections.

scholarly journals Tuberculosis epididymo-orchitis following intravesical bacillus Calmette-Guérin immunotherapy

2019 ◽  
Vol 2019 (7) ◽  
Author(s):  
Sean Rezvani ◽  
Gerald Collins
Keyword(s):  
Bladder Cancer ◽  
Side Effects ◽  
Mycobacterium Bovis ◽  
Superficial Bladder Cancer ◽  
Rare Complication ◽  
Bacillus Calmette Guerin ◽  
Radiological Findings ◽  
Life Threatening ◽  
Established Treatment

Abstract BCG is a well-established treatment for superficial bladder cancer. Although usually well-tolerated, side effects can range from mild cystitis to life-threatening sepsis. Epididymitis is a rare complication of BCG, with only a handful of cases proven to be caused directly by Mycobacterium bovis. We describe one such case, along with radiological findings for this rare complication.

1570: Combined Mitomycin C and Hyperthermia (SYNERGO) for Patients with Superficial Bladder Cancer (SBC) after Bacillus Calmette-Guerin (BCG) Failure

2007 ◽  
Vol 177 (4S) ◽  
pp. 519-519
Author(s):  
Ofer Nativ ◽  
Renzo Colombo ◽  
Dov Engelstein ◽  
Ofer N. Gofrit ◽  
Thomas Akkad ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mitomycin C ◽  
Superficial Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Bcg Failure

scholarly journals Granulomatous Hepatitis Following Intra-Vesical Instillation of Bacillus Calmette–Guérin for Treatment of Bladder Cancer

2021 ◽  
Vol 13 (3) ◽  
pp. 611-618
Author(s):  
Elsa Alves Branco ◽  
Raquel Duro ◽  
Teresa Brito ◽  
António Sarmento
Keyword(s):  
Bladder Cancer ◽  
Hepatitis A ◽  
Adverse Reactions ◽  
Superficial Bladder Cancer ◽  
Rare Complication ◽  
Immunocompetent Patient ◽  
Clinical Suspicion ◽  
Bacillus Calmette Guerin ◽  
Granulomatous Hepatitis ◽  
Appropriate Treatment

Intra-vesical instillation of bacillus Calmette–Guérin (BCG) is an important treatment modality of superficial bladder cancer. It is usually well tolerated, although some adverse reactions can occur. One possible yet rare complication is granulomatous hepatitis, that is thought to be caused either by BCG infection or a hypersensitivity reaction to the bacillus. We present a case of a 79-year-old apparently immunocompetent patient who developed granulomatous hepatitis a few months after BCG administration for bladder cancer immunotherapy. It is important to notice that acid-fast smears and cultures are often negative, and these should not exclude diagnosis nor delay treatment. Our case highlights the importance of clinical suspicion and prompt initiation of appropriate treatment.

A Low Dose Bacillus Calmette-Guerin Regimen in Superficial Bladder Cancer Therapy: Is it Effective?

1991 ◽  
Vol 146 (1) ◽  
pp. 32-35 ◽  
Author(s):  
Francesco Pagano ◽  
Pierfrancesco Bassi ◽  
Claudio Milani ◽  
Agostino Meneghini ◽  
Daniele Maruzzi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Therapy ◽  
Low Dose ◽  
Superficial Bladder Cancer ◽  
Bacillus Calmette Guerin

scholarly journals The double-sided effects of Mycobacterium Bovis bacillus Calmette–Guérin vaccine

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Junli Li ◽  
Lingjun Zhan ◽  
Chuan Qin
Keyword(s):  
Literature Review ◽  
Experimental Evidence ◽  
Mycobacterium Bovis ◽  
Virus Disease ◽  
Bcg Vaccine ◽  
Bacillus Calmette Guerin ◽  
Mycobacterial Infections ◽  
Specific Effects ◽  
Mycobacterial Diseases ◽  
Protection Mechanisms

AbstractBacillus Calmette–Guérin (BCG), the only vaccine proven to be effective against tuberculosis (TB), is the most commonly used vaccine globally. In addition to its effects on mycobacterial diseases, an increasing amount of epidemiological and experimental evidence accumulated since its introduction in 1921 has shown that BCG also exerts non-specific effects against a number of diseases, such as non-mycobacterial infections, allergies and certain malignancies. Recent Corona Virus Disease 2019 (COVID-19) outbreak has put BCG, a classic vaccine with significant non-specific protection, into the spotlight again. This literature review briefly covers the diverse facets of BCG vaccine, providing new perspectives in terms of specific and non-specific protection mechanisms of this old, multifaceted, and controversial vaccine.

Determination of Bacillus Calmette-Guerin Concentration Integrated in Delivery Materials for Intravesical Infusion Therapy of Superficial Bladder Cancer

2013 ◽  
Vol 655-657 ◽  
pp. 1917-1922 ◽  
Author(s):  
Cheng Ge Wu ◽  
Kang Ning Sun ◽  
Ai Min Li ◽  
Xiao Ning Sun
Keyword(s):  
Bladder Cancer ◽  
Reliable Method ◽  
Superficial Bladder Cancer ◽  
The Other ◽  
Infusion Therapy ◽  
Bacillus Calmette Guerin ◽  
Experiment Study ◽  
Characteristic Peak ◽  
Integrated Delivery

Purpose: To assess determination of Bacillus Calmette-Guerin(BCG) concentration integrated in delivery materials for intravesical infusion therapy of superficial bladder cancer. Material and Methods: The standard BCG solution was prepared and divided into two groups. One group was measured by spectrophotometer direct, the other group was determined by using enzyme mark instrument after the solution had cultured. The preliminary experiment study on BCG integrated delivery materials was finished by XTT method. Results: The wavelength of the characteristic peak changes with the variety of the concentration measured by spectrophotometer direct. The concentration of BCG which was embeded in integrated delivery materials for intravesical infusion therapy of superficial bladder cancer was linear with absorbance at 450nm by XTT method in the selected range. Conclusions: It is an incorrect way to measure BCG concentration like determining other solutions by the spectrophotometer immediately and direct. It is the simple, rapid and reliable method by XTT method to study on the performance of the BCG concentration integrated in delivery materials for Intravesical infusion therapy of superficial bladder cancer.

scholarly journals INTRAVESICAL BACILLUS CALMETTE-GUERIN (BCG) IN THE TREATMENT OF SUPERFICIAL BLADDER CANCER

1990 ◽  
Vol 81 (7) ◽  
pp. 997-1001 ◽  
Author(s):  
Tadashi Yamamoto ◽  
Masamichi Hagiwara ◽  
Masaaki Nakazono ◽  
Hidenobu Yamamoto
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Bacillus Calmette Guerin
Sign in / Sign up

Export Citation Format

Share Document